Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

ISTO Technologies Announces New Chief Financial Officer

Dec 5, 2007

St. Louis, MO December 5, 2007 — ISTO Technologies, Inc., a privately held orthobiologic company, today announced that Scott Gill has joined its executive management team as Chief Financial Officer. Prior to joining ISTO, Mr. Gill was a Director in the Investment Banking group at A.G. Edwards & Sons. In that capacity, he worked with a number of emerging growth public and private companies on a variety of capital raising and strategic advisory assignments, with a particular emphasis on M&A transactions for clients in the healthcare sector. Before joining A.G. Edwards in 1998, Mr. Gill was a Senior Financial Analyst with Anheuser-Busch, Inc. He received his Bachelor of Arts in economics from the University of Tennessee and his Master of Business Administration from the Kellogg School of Management at Northwestern University.
“I am pleased to welcome Scott to ISTO,” said Mitchell Seyedin Ph.D., President and CEO of ISTO. “We are delighted to be able to attract an individual of his caliber and experience. His nine years with A.G. Edwards in strategic planning and business development roles make him an ideal fit, and the timing is right for us to leverage his skills to prepare ISTO for its next growth phase,” said Seyedin.
ISTO’s rich product pipeline includes DeNovo® ET, a tissue engineered cartilage implant in clinical trials for resurfacing knee joints, NuQu™, a cartilage cell-based product in late-stage development for degenerated disc nucleus, and InQu, a biomaterial for bone regeneration that has received 510K clearance. ISTO’s innovative products are designed to address very large markets and unmet clinical needs. Cartilage regeneration is often called the “holy grail” of the orthopedic industry because of its potential to restore function to damaged joints that otherwise have limited healing potential. Cartilage serves as a “shock absorber” protecting all joints, including spinal discs, from the wear and tear experienced during motion. InQu represents a new class of biomaterial designed to offer a number of clinical advantages to surgeons and patients.


About ISTO Technologies, Inc.

ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO’s products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at www.istobiologics.com or contact the Company at 314-995-6049.

To top